BioMedha is a UK-based pre-clinical CRO providing in vitro biology expertise to the global drug discovery industry. We are industry-experienced, in vitro biology-focused scientists and can add significant value to our client programmes by undertaking key elements of the early stage drug discovery process. BioMedha expertise includes: • Access to fresh whole blood, Whole blood assays, Immune cell isolation, differentiation, and functional assays • Immunology, Oncology, Immuno-oncology, and inflammation studies • Target validation, assay development, and compound screening, and Mechanism of action studies • Flow cytometry capabilities • Cytokine assays and Luminex multiplexing • Cell imaging expertise • Expression studies (protein levels by western blot/ELISA, mRNA levels by qPCR, and surface expression by Flowcyte) • Clariostar Multimode plate reader-based assays (Fluorescence, Luminesce, FP, FRET, BRET, Alphascreen, HTRF) • Functional Studies (e.g. signalling pathways, bioassays) • GPCRs: Assay development and screening • Protein-Protein Interactions (PPI) • Enzyme activity • Discovery Toxicology studies We are a small but passionate team of scientists with substantial experience in the pharmaceutical and biotech industries, focused heavily on pre-clinical drug discovery biology. We serve clients in pharma, biotech, virtual companies, spin-outs, and academic institutions.
